Immune checkpoint inhibitors activate the host immune system to defend against tumors, and although this cancer therapy has shown remarkable success today, the chances of patient response to the therapy are stillRead More…
The 10th Annual Immuno-Oncology Summit was held in Boston during October 12-14, 2022. Creative Biolabs, as an exhibitor, attended the 10th Annual Immuno-Oncology Summit at booth #9 and has attracted many attendeesRead More…
On July 9th, Fate Therapeutics announced that U.S. Food and Drug Administration has approved the first IND application for iPSC-derived allogeneic CAR-T cell therapy FT819 for the treatment of recurrent/refractory B-cell malignant tumors,Read More…
Ten years ago, scientists announced the development of cancer immunotherapy called chimeric antigen receptor-T cell (CAR-T) therapy: genetically modifying T cells from patients to make them powerful anti-tumor effects, and then infusingRead More…
Recently, it was announced that LineaRx (a part of Applied DNA Science), a company specializing in next-generation biotherapy, has achieved anti-CD19-CAR (chimeric antigen receptor) expression on human T cells through its proprietaryRead More…
More and more cancer patients are receiving a promising new treatment called CAR-T cell therapy. In this treatment, the patient’s own T cells are removed from the body and genetically modified toRead More…
Scientists have been hugely successful in developing a new type of anti-cancer therapy, immunotherapy, over the past decade, a treatment that attacks cancer cells by activating the body’s autoimmune system. One of theRead More…
Scientists at Stanford University developed a new CAR-T therapy that can eradicate many types of childhood tumors in a mouse study, which was published in Clinical Cancer Research on January 17, furtherRead More…
The unique advantages of CAR-T therapy in the treatment of hematological tumors have once again become a hot spot for the recent American Society of Hematology (ASH) Annual Meeting, and bispecific antibodiesRead More…
In a new study, researchers from the Mayo Clinic in the United States have developed a new strategy that may improve the performance of chimeric antigen receptor T (CAR-T) cell therapy inRead More…